The Human IGF-1 (Insulin-Like Growth Factor 1) ELISA Kit Market includes a broad range of products designed for the measurement of insulin-like growth factor 1 in clinical and research settings. The market was valued at USD 693.4 million in 2025 and is forecast to reach USD 1.2 billion by 2035, growing at a CAGR of 5.6%.

By application, the market is divided into clinical diagnostics, research and development, hormone level measurement, and drug discovery. Clinical diagnostics represents a major application area because accurate IGF-1 testing can support the assessment of conditions associated with growth and hormone regulation.

By end use, the market includes hospitals, clinical laboratories, research institutes, and pharmaceutical companies. Pharmaceutical companies and research organizations use ELISA kits extensively in laboratory investigations and drug development programs.

The kit-type segment includes standard kits, high-sensitivity kits, and custom kits. Detection methods include colorimetric, fluorescent, and chemiluminescent technologies. These different options allow laboratories to select products based on sensitivity, workflow, and research requirements.

Key companies identified in the market include Promega, Thermo Fisher Scientific, MilliporeSigma, PeproTech, R&D Systems, Abcam, BioVendor, MyBioSource, Enzo Life Sciences, and RayBiotech.

North America is expected to lead the market, while Europe remains an important biotechnology and diagnostics region. Asia-Pacific is projected to offer significant growth opportunities as research capabilities and healthcare investment expand.

Product innovation, improved assay performance, strategic partnerships, and expanding research applications are expected to influence the competitive landscape.